Ipsen Group Overview

  • Founded
  • 1929

Founded
  • Status
  • Public

  • Employees
  • 5,744

Employees
  • Stock Symbol
  • IPN

Stock Symbol
  • Investments
  • 27

  • Share Price
  • $91.37

  • (As of Thursday Closing)

Ipsen Group General Information

Description

Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: Specialty care and Consumer Healthcare. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focus on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Website
www.ipsen.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Commercial Services
Stock Exchange
PAR
Primary Office
  • 65, Quai Georges Gorse
  • 92100 Boulogne Billancourt
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ipsen Group Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$91.37 $89.84 $84.37 - $131.96 $7.54B 82.5M 112K $9.25

Ipsen Group Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 7,634,773 7,634,773 7,469,472 8,328,283
Revenue 3,545,832 3,545,832 3,061,920 3,014,329
EBITDA 1,267,661 1,267,661 903,153 186,835
Net Income 764,474 764,474 624,672 (56,756)
Total Assets 5,668,803 5,668,803 5,304,847 4,824,469
Total Debt 784,742 784,742 1,071,055 1,134,958
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ipsen Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ipsen Group‘s full profile, request access.

Request a free trial

Ipsen Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, e
Pharmaceuticals
Boulogne Billancourt, France
5,744 As of 2021
00000
00000000000 00000

000000

tur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad m
00000 0000000000 00000000
Paris, France
00000 As of 0000
000000000000

000000

tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
000000000000000
Basel, Switzerland
000000 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ipsen Group Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sanofi Corporation Paris, France 00000 000000000000
00000000 Corporation Basel, Switzerland 000000 000000000000
000000 00000000000 Corporation Parma, Italy 0000
000000000000000 Corporation Brentford, United Kingdom 00000 000000000
000000000 Private Equity-Backed Milan, Italy 0000 000000000000
You’re viewing 5 of 10 competitors. Get the full list »

Ipsen Group Patents

Ipsen Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200383894-A1 Treatment of moderate to very severe glabellar lines and lateral canthal lines Pending 07-Jun-2019 00000000000
GB-201907016-D0 Screening method to determine suitability for participation in a clinical trial Ceased 17-May-2019 00000000000
EP-3911742-A1 Sortase-labelled clostridium neurotoxins Pending 16-Jan-2019 00000000
EP-3890772-A1 Treatment of symptoms of traumatic brain injury Pending 05-Dec-2018 00000000000
EP-3888097-A1 Dosing calculator for spasticity Pending 27-Nov-2018 G16H20/10
To view Ipsen Group’s complete patent history, request access »

Ipsen Group Executive Team (27)

Name Title Board Seat Contact Info
David Loew Chief Executive Officer & Board Member
Aymeric Le Chatelier Executive Vice President & Group Chief Financial Officer
Dominique Laymand Executive Vice-President & Chief Ethics and Compliance Officer
Philippe Lopes-Fernandes Chief Business Officer & Executive Vice President
Francois Garnier Executive Vice President, General Counsel and Chief Business Ethics Officer
You’re viewing 5 of 27 executive team members. Get the full list »

Ipsen Group Board Members (13)

Name Representing Role Since
0000 00000000 Ipsen Group Board Member 000 0000
0000000 0000000 Ipsen Group Board Member & Vice Chairman 000 0000
00000 000000 Self Board Member 000 0000
00000 0000 Ipsen Group Chief Executive Officer & Board Member 000 0000
00000 00000000 Ipsen Group Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Ipsen Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ipsen Group Investments & Acquisitions (27)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 27-Jun-2022 0000000000 00000 Drug Discovery 00000 000
0000 00000000 18-Nov-2021 00000 0000 0000 Drug Discovery 00000000
0000000 01-Jan-2021 00000 0000 Drug Discovery
0000000 15-Jun-2020 0000 00000 00.000 Enterprise Systems (Healthcare)
Clementia Pharmaceuticals 18-Apr-2019 Merger/Acquisition 00.000 Biotechnology 00000 000
You’re viewing 5 of 27 investments and acquisitions. Get the full list »

Ipsen Group Subsidiaries (3)

Company Name Industry Location Founded
Canbex Therapeutics Drug Discovery London, United Kingdom 2005
00000 000000000000 Biotechnology Basking Ridge, NJ 0000
00000 00000000 Venture Capital Boulogne Billancourt, France
To view Ipsen Group’s complete subsidiaries history, request access »

Ipsen Group Exits (7)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 16-Feb-2017 000000000 0000 Completed
  • 7 buyers
00000 000000000000 13-Aug-2015 00000 00000 00 0000 Completed
  • 8 buyers
000000 00000000000 13-Aug-2015 00000 00000 00 0000 Completed
  • 9 buyers
000000 00000000000 29-Jul-2013 00000 00000 00 0000 Completed
  • 7 buyers
Inserm Transfert 12-Jan-2012 Later Stage VC 000.00 Completed
  • 8 buyers
You’re viewing 5 of 7 exits. Get the full list »